Prima Biomed Ltd (PBMD) 1.03 $PBMD Prima Reports

New Post Public Reply Private Reply Replies (0) Message Board

Jun 24, 2016 at 5:19 AM

Prima Biomed Ltd (PBMD) 1.03 $PBMD

Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 1.03 (+0.01), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), CELG: 100.66 (+1.43)

Prima BioMed to Maintain NASDAQ Listing
Marketwired - Mon Jun 06, 8:25PM CDT
SYDNEY, AUSTRALIA--(Marketwired - Jun 6, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock Market indicating that the Company's American Depositary Shares have maintained a closing bid price of US$1.00 per share or greater for 10 consecutive business days from 20 May 2016 to 3 June 2016. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule"

and the Company's American Depositary Shares will remain listed on the NASDAQ Global Market.
PBMD: 1.03 (+0.01)

Prima BioMed Enters Into Sale and Licensing Agreement With Sydys to Advance CVac(TM) Program
Marketwired - Thu May 12, 3:26AM CDT
SYDNEY, AUSTRALIA and SEATTLE, WA--(Marketwired - May 12, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 1.03 (+0.01)

Prima BioMed Limited (NASDAQ: PBMD) Analyst Coverage Initiated
ACCESSWIRE - Tue May 03, 7:05AM CDT
SYDNEY, AUSTRALIA / ACCESSWIRE / May 3, 2016 / Prima BioMed Limited (NASDAQ: PBMD) an Australia-based biotechnology company engaged in research, development and commercialization of licensed medical biotechnology, recently announced the granting of patent number 5908210 entitled "Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response" by the Japanese Patent Office. This patent relates to Prima's IMP321 and its use either alone, or in combination, for immunotherapeutic or chemotherapeutic purposes to induce an increase in circulating monocyte numbers in order to protect against cancer. This patent will therefore support the use of IMP321 as it is being used in Prima's AIPAC trial in metastatic breast cancer. Patent expiry is expected to be 3rd of October 2028.
PBMD: 1.03 (+0.01)

Top Stocks on 4/20: Investors Are Considering These on Wednesday April 20th
ACCESSWIRE - Wed Apr 20, 11:57AM CDT
MIAMI, FL / ACCESSWIRE / April 20, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EBIO, ASM, OCLS, and PBMD have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
PBMD: 1.03 (+0.01), EBIO: 2.29 (-0.04), OCLS: 0.83 (unch)

IMP321 Safety and Immune Monitoring Data Published in Clinical Cancer Research Journal
Marketwired - Tue Mar 15, 2:40AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) advises that safety and immune monitoring data from an investigator-led clinical trial in melanoma using IMP321 as an adjuvant to a therapeutic vaccine has been published in the March 15 edition of the Clinical Cancer Research journal. The paper is titled "Vaccination with sLAG-3-Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients: report of a phase I/IIa clinical trial" and is the result of a long-standing academic collaboration between Dr. Frederic Triebel, Prima's Chief Scientific Officer and Chief Medical Officer and scientists at the Ludwig Centre for Cancer Research at the University of Lausanne, Switzerland.
PBMD: 1.03 (+0.01)

Prima Biomed (PBMD) Jumps: Stock Adds 25.6% in Session
Zacks Equity Research - Zacks Investment Research - Fri Mar 11, 7:15AM CST
Prima Biomed Ltd. (PBMD) shares rose almost 26% in the last trading session.
PBMD: 1.03 (+0.01), ANIK: 51.10 (+0.83)

Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency
Marketwired - Fri Mar 04, 12:35AM CST
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima," the "Company"

, has received notification from the Listing Qualifications Department of The NASDAQ Stock Market (the "Staff"

indicating that, for the period from January 13, 2016 through February 26, 2016, the closing bid price of the Company's American Depositary Shares, or ADS, had not been maintained at the minimum required closing bid price of at least US$1.00 per share as required for continued listing on The NASDAQ Global Market pursuant to NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule"

.
PBMD: 1.03 (+0.01)

Prima BioMed wins US patent for IMP731 Antibody
M2 - Thu Jan 28, 3:34AM CST
Biotechnology company Prima BioMed (ASX

RR) (NASDAQ

BMD) disclosed on Wednesday the receipt of the patent entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" from the US Patent and Trademark Office.
PBMD: 1.03 (+0.01)

US Patent Grants for IMP731 Antibody
Marketwired - Wed Jan 27, 5:00PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company"

announces the granting of patent number US 9,244,059 entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" by the United States Patent and Trademark Office.
PBMD: 1.03 (+0.01)

Prima BioMed to start Phase I melanoma study of IMP321 across Australia
M2 - Wed Jan 27, 3:16AM CST
Immuno-oncology company Prima BioMed (ASX

RR) (NASDAQ

BMD) announced on Tuesday that TACTI-mel, a Phase I clinical study in melanoma using its lead compound IMP321, will now commence in the Gallipoli Medical Research Foundation at the Greenslopes Private Hospital in Queensland, Austrlaia.
PBMD: 1.03 (+0.01)

Prima BioMed Initiates Phase I Melanoma Study in Australia
Marketwired - Tue Jan 26, 4:51PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce the initiation of the first clinical trial site for TACTI-mel, a Phase I clinical study in melanoma using its lead compound IMP321, to be conducted in Australia.
PBMD: 1.03 (+0.01)

Prima BioMed Initiates Phase IIb Study in Metastatic Breast Cancer
Marketwired - Tue Dec 22, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 1.03 (+0.01)

4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Fri Dec 11, 8:51AM CST
NEW YORK, NY / ACCESSWIRE / December 11, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
EYES: 3.78 (+0.04), PBMD: 1.03 (+0.01), CGEN: 7.00 (+0.05), ONTY: 1.21 (+0.02)

Prima BioMed Progresses Japanese Collaboration
Marketwired - Fri Dec 11, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) today announces important progress in its collaboration with NEC Corporation and Yamaguchi University in Japan. In this collaboration, first announced in May 2015, Prima's IMP321 Antigen Presenting Cell activator (APC) is being combined with a therapeutic vaccine for different carcinoma types that was developed at Yamaguchi University.
PBMD: 1.03 (+0.01)

Prima BioMed Unveils Phase I Combination Study of IMP321 + Checkpoint Inhibitor
Marketwired - Wed Nov 18, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 1.03 (+0.01)

Prima BioMed announces AUD2.0m from equity placement with an Australian Institution
M2 - Mon Nov 02, 4:19AM CST
Immuno-oncology company Prima BioMed (ASX

RR) (NASDAQ

BMD) said on Friday that it has raised AUD2.0m in an equity placement with an Australian Institution.
PBMD: 1.03 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ROKFORM Unleashes Rangefinder 18X with Bold Features

Strong Magnets and Smarter Tracking: A Golfer's Companion Forget about the agony of misplacing that pricey bit of tech you thought was secure on your golf cart. ROKFORM's new Rangefinder 18X promises to stick around with its bold tech debut. We're talking a magnet on steroids here—up to three times stronger than the competition. If your last purchase slipped on a bumpy...

Grid Hurdles Stalling Industrial Heat's Future Growth

The Grid's the New Ball and Chain Now that we're done fiddling with tech, let's talk grid. The industrial players itching to switch to electric heat have found a new villain: the grid. You'd think with resistance heating, electric boilers, electric arc furnaces, and the whole shebang ready to roll, it’d be a smooth ride. But nope, the bottleneck's the bloodstream...

MLS Org's Sue Compass to Safeguard Fair Listing Access

Real Estate Clash: MLS vs. Compass Imagine flipping on the TV to see a legal showdown brewing in the real estate world — you've got six heavy-hitter MLSs facing off against Compass, Inc. Yeah, we're talking a legal slugfest here, folks, as these MLSs rally to keep the playing field level for over 120,000 agents across the country. They're not messing around, bringing a...

Sheep Meet Solar: Maryland's Agrivoltaics Unfurled

Who would have thought sheep could be power players in Maryland's clean energy scene? But here we are, staring at a field in Cooksville where eighty sheep graze under the watchful gaze of solar panels. It’s not your everyday scene, but it’s a sign of the times when energy meets agriculture head-on. The Unlikely Marriage of Solar and Sheep What we’re looking at is a...

LEDC and Crosson Lead the Charge in Community Finance

Recognizing Game-Changers in Community Development Finance In the financial landscape, it's not always about the big tickers and glitzy IPOs. Sometimes, it's the intrepid ground-level players who make the real difference. That's exactly what happened when the Opportunity Finance Network (OFN) held its 42nd annual conference in New Orleans, honoring standouts in the realm...

College Athletics Needs a New Business Revolution

Wake Up Call for College Athletics Here's a heads-up—college sports aren't just about cheering fans and game-day jerseys anymore. It's high time universities start thinking of athletics as businesses, blending the thrill of game day with the realities of financial statements. Michael Schreiber rang this bell loud and clear on the 'Disruption Interruption' podcast,...

China's Sewing Machine Exports: Global Expansion Surge

China's Position as a Sewing Machine Powerhouse It seems like the global sewing machine market is having a bit of a renaissance, and China's sitting pretty right at the center. You see, places like Taizhou in Zhejiang Province aren’t just pushing out volume—they're slamming market demand with innovation and precision. Once known primarily as the manufacturing hub,...

Frost & Sullivan Boosts China Insight with LeadLeo

Navigating China's Complex Market Landscape You've got to understand, the stakes in China are like a high-wire act—mystifying and risky, yet bountiful if you play your cards right. Frost & Sullivan's latest maneuver into China's business intel scene is basically the lifeline for navigating this increasingly convoluted market. With China surging ahead in AI, biotech, and...

LifeWave's Bold New Path in Human Performance

Redefining the Everyday Athlete Not every day you see a wellness company talking about 'performance' in the broader human sense. Not just for the pros or those beating personal records but for anyone looking to lift the quality of their daily grind. That's the new line LifeWave's drawing in the sand with their spiffy 'Human Performance Technology.' They're looking to...

Monigle's 7 Transform Awards: Building Human Connections

Award-Winning Branding with Heart Alright, let’s dig into Monigle's world—a place where branding isn't just a static logo slapped on anything that moves but is instead about creating alive, breathing experiences that genuinely connect with people. They didn't just turn heads at the Transform Awards North America, they're the ones with jaws dropping, folks. Seven...